-
1
-
-
33745726677
-
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
-
16822992 10.1056/NEJMoa055531 1:CAS:528:DC%2BD28Xms1Chsrw%3D
-
D Cunningham WH Allum SP Stenning, et al. 2006 Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer New Engl J Med 355 1 11 20 16822992 10.1056/NEJMoa055531 1:CAS:528:DC%2BD28Xms1Chsrw%3D
-
(2006)
New Engl J Med
, vol.355
, Issue.1
, pp. 11-20
-
-
Cunningham, D.1
Allum, W.H.2
Stenning, S.P.3
-
2
-
-
0035818048
-
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction
-
11547741 10.1056/NEJMoa010187 1:STN:280:DC%2BD3Mvps1Cqug%3D%3D
-
JS Macdonald SR Smalley J Benedetti, et al. 2001 Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction New Engl J Med 345 10 725 730 11547741 10.1056/NEJMoa010187 1:STN:280:DC%2BD3Mvps1Cqug%3D%3D
-
(2001)
New Engl J Med
, vol.345
, Issue.10
, pp. 725-730
-
-
MacDonald, J.S.1
Smalley, S.R.2
Benedetti, J.3
-
3
-
-
38049047178
-
Capecitabine and oxaliplatin for advanced esophagogastric cancer
-
18172173 10.1056/NEJMoa073149 1:CAS:528:DC%2BD1cXisFSktg%3D%3D
-
D Cunningham N Starling S Rao, et al. 2008 Capecitabine and oxaliplatin for advanced esophagogastric cancer New Engl J Med 358 1 36 46 18172173 10.1056/NEJMoa073149 1:CAS:528:DC%2BD1cXisFSktg%3D%3D
-
(2008)
New Engl J Med
, vol.358
, Issue.1
, pp. 36-46
-
-
Cunningham, D.1
Starling, N.2
Rao, S.3
-
4
-
-
33750949065
-
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group
-
17075117 10.1200/JCO.2006.06.8429
-
E Van Cutsem VM Moiseyenko S Tjulandin, et al. 2006 Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group J Clin Oncol 24 31 4991 4997 17075117 10.1200/JCO.2006.06.8429
-
(2006)
J Clin Oncol
, vol.24
, Issue.31
, pp. 4991-4997
-
-
Van Cutsem, E.1
Moiseyenko, V.M.2
Tjulandin, S.3
-
6
-
-
67650410007
-
Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site
-
19531677 10.1158/1055-9965.EPI-09-0250
-
H Wu JA Rusiecki K Zhu, et al. 2009 Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site Cancer Epidemiol Biomarkers Prev 18 7 1945 1952 19531677 10.1158/1055-9965.EPI-09-0250
-
(2009)
Cancer Epidemiol Biomarkers Prev
, vol.18
, Issue.7
, pp. 1945-1952
-
-
Wu, H.1
Rusiecki, J.A.2
Zhu, K.3
-
7
-
-
77952002277
-
Gastric cancer: A primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease
-
20410336 1:CAS:528:DC%2BC3cXlvFOls7c%3D
-
MA Shah DP Kelsen 2010 Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease J Natl Compr Canc Netw 8 4 437 447 20410336 1:CAS:528: DC%2BC3cXlvFOls7c%3D
-
(2010)
J Natl Compr Canc Netw
, vol.8
, Issue.4
, pp. 437-447
-
-
Shah, M.A.1
Kelsen, D.P.2
-
8
-
-
80051486834
-
Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy
-
21684283 10.1053/j.gastro.2011.04.042 Description of two distinct molecular subtypes of gastric cancer using gene expression profiling plus validation in four separate patient cohorts.
-
IB Tan T Ivanova Lim KH, et al. 2011 Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy Gastroenterology 141 2 476 485.e11 21684283 10.1053/j.gastro.2011.04.042 Description of two distinct molecular subtypes of gastric cancer using gene expression profiling plus validation in four separate patient cohorts.
-
(2011)
Gastroenterology
, vol.141
, Issue.2
-
-
Tan, I.B.1
Ivanova, T.2
Lim, K.H.3
-
9
-
-
79955500519
-
Molecular classification of gastric cancer: A new paradigm
-
21430069 10.1158/1078-0432.CCR-10-2203 1:CAS:528:DC%2BC3MXlsVGhu7s%3D
-
MA Shah R Khanin L Tang, et al. 2011 Molecular classification of gastric cancer: a new paradigm Clin Cancer Res 17 9 2693 2701 21430069 10.1158/1078-0432.CCR-10-2203 1:CAS:528:DC%2BC3MXlsVGhu7s%3D
-
(2011)
Clin Cancer Res
, vol.17
, Issue.9
, pp. 2693-2701
-
-
Shah, M.A.1
Khanin, R.2
Tang, L.3
-
10
-
-
84862777035
-
A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
-
Comprehensive review of genomic landscape of gastric cancer
-
Deng N, Goh LK, Wang H, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012. Comprehensive review of genomic landscape of gastric cancer.
-
(2012)
Gut
-
-
Deng, N.1
Goh, L.K.2
Wang, H.3
-
11
-
-
79251593630
-
Oncogenic mutations in gastric cancer with microsatellite instability
-
20937558 10.1016/j.ejca.2010.09.008 1:CAS:528:DC%2BC3MXhtlSqsrs%3D
-
G Corso S Velho J Paredes, et al. 2011 Oncogenic mutations in gastric cancer with microsatellite instability Eur J Cancer 47 3 443 451 20937558 10.1016/j.ejca.2010.09.008 1:CAS:528:DC%2BC3MXhtlSqsrs%3D
-
(2011)
Eur J Cancer
, vol.47
, Issue.3
, pp. 443-451
-
-
Corso, G.1
Velho, S.2
Paredes, J.3
-
12
-
-
77956262693
-
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial
-
20728210 10.1016/S0140-6736(10)61121-X 1:CAS:528:DC%2BC3cXhtVymt7zO First phase III randomised trial demonstrating evidence of efficacy of targeted agent for treatment of gastric cancer.
-
Y-J Bang E Van Cutsem A Feyereislova, et al. 2010 Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 9742 687 697 20728210 10.1016/S0140-6736(10)61121-X 1:CAS:528:DC%2BC3cXhtVymt7zO First phase III randomised trial demonstrating evidence of efficacy of targeted agent for treatment of gastric cancer.
-
(2010)
Lancet
, vol.376
, Issue.9742
, pp. 687-697
-
-
Bang, Y.-J.1
Van Cutsem, E.2
Feyereislova, A.3
-
13
-
-
84862914692
-
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
-
22149875 10.1056/NEJMoa1113216 1:CAS:528:DC%2BC38XhtFSlt7Y%3D
-
J Baselga J Cortés S-B Kim, et al. 2012 Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer New Engl J Med 366 2 109 119 22149875 10.1056/NEJMoa1113216 1:CAS:528:DC%2BC38XhtFSlt7Y%3D
-
(2012)
New Engl J Med
, vol.366
, Issue.2
, pp. 109-119
-
-
Baselga, J.1
Cortés, J.2
Kim, S.-B.3
-
14
-
-
79952092706
-
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy
-
21172893 10.1200/JCO.2010.29.5865 1:CAS:528:DC%2BC3MXivFWmsrc%3D
-
HA Burris HS Rugo SJ Vukelja, et al. 2011 Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy J Clin Oncol 29 4 398 405 21172893 10.1200/JCO.2010.29.5865 1:CAS:528:DC%2BC3MXivFWmsrc%3D
-
(2011)
J Clin Oncol
, vol.29
, Issue.4
, pp. 398-405
-
-
Burris, H.A.1
Rugo, H.S.2
Vukelja, S.J.3
-
15
-
-
80054057131
-
Southwest Oncology Group study S0413: A phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer
-
Iqbal S, Goldman B, Fenoglio-Preiser CM, et al. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Annals of Oncology 2011.
-
(2011)
Annals of Oncology
-
-
Iqbal, S.1
Goldman, B.2
Fenoglio-Preiser, C.M.3
-
16
-
-
77953453066
-
Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: Phase II efficacy and biomarker analyses
-
abstr 43
-
Hecht J, Urba G, Koehler M, Ellis C. Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: phase II efficacy and biomarker analyses. Proc GI ASCO 2008;43(abstr 43).
-
(2008)
Proc GI ASCO
, pp. 43
-
-
Hecht, J.1
Urba, G.2
Koehler, M.3
Ellis, C.4
-
17
-
-
84861184026
-
A global, multicenter phase II trial of lapatinib plus capecitabine in gastric cancer
-
abstr 88
-
Pishvaian M, Sakaeva D, Hsieh RK. A global, multicenter phase II trial of lapatinib plus capecitabine in gastric cancer. J Clin Oncol 2011;29(suppl 4; abstr 88).
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL. 4
-
-
Pishvaian, M.1
Sakaeva, D.2
Hsieh, R.K.3
-
18
-
-
42649133793
-
EGFR in gastric carcinomas: Prognostic significance of protein overexpression and high gene copy number
-
18397279 10.1111/j.1365-2559.2008.03021.x 1:CAS:528:DC%2BD1cXks1Wht70%3D
-
MA Kim HS Lee HE Lee, et al. 2008 EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number Histopathology 52 6 738 746 18397279 10.1111/j.1365-2559.2008.03021.x 1:CAS:528: DC%2BD1cXks1Wht70%3D
-
(2008)
Histopathology
, vol.52
, Issue.6
, pp. 738-746
-
-
Kim, M.A.1
Lee, H.S.2
Lee, H.E.3
-
19
-
-
79952847624
-
A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus
-
21425140 10.1002/cncr.25602 1:CAS:528:DC%2BC3MXkslWiu7g%3D
-
DH Ilson D Kelsen M Shah, et al. 2011 A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus Cancer 117 7 1409 1414 21425140 10.1002/cncr.25602 1:CAS:528:DC%2BC3MXkslWiu7g%3D
-
(2011)
Cancer
, vol.117
, Issue.7
, pp. 1409-1414
-
-
Ilson, D.H.1
Kelsen, D.2
Shah, M.3
-
20
-
-
33750618860
-
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127
-
17050876 10.1200/JCO.2006.07.1316 1:CAS:528:DC%2BD28Xht1eiu73L
-
T Dragovich S McCoy CM Fenoglio-Preiser, et al. 2006 Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127 J Clin Oncol 24 30 4922 4927 17050876 10.1200/JCO.2006.07.1316 1:CAS:528:DC%2BD28Xht1eiu73L
-
(2006)
J Clin Oncol
, vol.24
, Issue.30
, pp. 4922-4927
-
-
Dragovich, T.1
McCoy, S.2
Fenoglio-Preiser, C.M.3
-
21
-
-
33645734242
-
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients
-
16575012 10.1200/JCO.2005.03.4900 1:CAS:528:DC%2BD28XjvFyktL4%3D
-
ML Janmaat MI Gallegos-Ruiz JA Rodriguez, et al. 2006 Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients J Clin Oncol 24 10 1612 1619 16575012 10.1200/JCO.2005.03.4900 1:CAS:528:DC%2BD28XjvFyktL4%3D
-
(2006)
J Clin Oncol
, vol.24
, Issue.10
, pp. 1612-1619
-
-
Janmaat, M.L.1
Gallegos-Ruiz, M.I.2
Rodriguez, J.A.3
-
22
-
-
35348826772
-
A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: Evidence of gene expression, cellular, and clinical response
-
17908981 10.1158/1078-0432.CCR-06-1970 1:CAS:528:DC%2BD2sXhtFSntLvP
-
DR Ferry M Anderson K Beddard, et al. 2007 A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response Clin Cancer Res 13 19 5869 5875 17908981 10.1158/1078-0432.CCR-06-1970 1:CAS:528:DC%2BD2sXhtFSntLvP
-
(2007)
Clin Cancer Res
, vol.13
, Issue.19
, pp. 5869-5875
-
-
Ferry, D.R.1
Anderson, M.2
Beddard, K.3
-
23
-
-
79957834501
-
A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma
-
21217058 10.1093/annonc/mdq604 1:STN:280:DC%2BC3MrkvFygsg%3D%3D
-
JA Chan LS Blaszkowsky PC Enzinger, et al. 2011 A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma Ann Oncol 22 6 1367 1373 21217058 10.1093/annonc/mdq604 1:STN:280:DC%2BC3MrkvFygsg%3D%3D
-
(2011)
Ann Oncol
, vol.22
, Issue.6
, pp. 1367-1373
-
-
Chan, J.A.1
Blaszkowsky, L.S.2
Enzinger, P.C.3
-
24
-
-
70349937924
-
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)
-
19773760 10.1038/sj.bjc.6605319 1:CAS:528:DC%2BD1MXht1GntbnN
-
C Pinto F Di Fabio C Barone, et al. 2009 Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study) Br J Cancer 101 8 1261 1268 19773760 10.1038/sj.bjc.6605319 1:CAS:528: DC%2BD1MXht1GntbnN
-
(2009)
Br J Cancer
, vol.101
, Issue.8
, pp. 1261-1268
-
-
Pinto, C.1
Di Fabio, F.2
Barone, C.3
-
25
-
-
33847663871
-
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
-
17164226 10.1093/annonc/mdl459 1:STN:280:DC%2BD2s7hsVKjsA%3D%3D
-
C Pinto F Di Fabio S Siena, et al. 2007 Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) Ann Oncol 18 3 510 517 17164226 10.1093/annonc/mdl459 1:STN:280:DC%2BD2s7hsVKjsA%3D%3D
-
(2007)
Ann Oncol
, vol.18
, Issue.3
, pp. 510-517
-
-
Pinto, C.1
Di Fabio, F.2
Siena, S.3
-
26
-
-
79958830832
-
Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: A prospective multi-center biomarker-oriented phase II study
-
Moehler M, Mueller A, Trarbach T, et al. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Annals of Oncology 2010.
-
(2010)
Annals of Oncology
-
-
Moehler, M.1
Mueller, A.2
Trarbach, T.3
-
27
-
-
79957539777
-
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
-
19997960 10.1007/s10637-009-9363-0 1:CAS:528:DC%2BC3MXhvVCiurk%3D
-
C Kim J-L Lee M-H Ryu, et al. 2011 A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer Invest New Drugs 29 2 366 373 19997960 10.1007/s10637-009-9363-0 1:CAS:528:DC%2BC3MXhvVCiurk%3D
-
(2011)
Invest New Drugs
, vol.29
, Issue.2
, pp. 366-373
-
-
Kim, C.1
Lee, J.-L.2
Ryu, M.-H.3
-
28
-
-
58749089260
-
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer
-
19127259 10.1038/sj.bjc.6604861 1:CAS:528:DC%2BD1MXpsVSrtg%3D%3D
-
SW Han DY Oh SA Im, et al. 2009 Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer Br J Cancer 100 2 298 304 19127259 10.1038/sj.bjc.6604861 1:CAS:528:DC%2BD1MXpsVSrtg%3D%3D
-
(2009)
Br J Cancer
, vol.100
, Issue.2
, pp. 298-304
-
-
Han, S.W.1
Oh, D.Y.2
Im, S.A.3
-
29
-
-
79951532484
-
CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer
-
abstr 4006
-
Enzinger P, Burtness B, Hollis D, Niedzwiecki D, Ilson D. CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. J Clin Oncol 2010;28(15s):p. abstr 4006.
-
(2010)
J Clin Oncol
, vol.28
, Issue.15 S
-
-
Enzinger, P.1
Burtness, B.2
Hollis, D.3
Niedzwiecki, D.4
Ilson, D.5
-
30
-
-
84859410722
-
Results of docetaxel plus oxaliplatin (DOCOX) with or without cetuximab in patients with metastatic gastric and/or gastroesophagel junction adenocarcinoma: Results of a randomized phase II study
-
abstr 4015
-
Richards DA, Kocs DM, Spira AI. Results of docetaxel plus oxaliplatin (DOCOX) with or without cetuximab in patients with metastatic gastric and/or gastroesophagel junction adenocarcinoma: Results of a randomized phase II study. J Clin Oncol 2011;29(suppl; abstr 4015).
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
-
-
Richards, D.A.1
Kocs, D.M.2
Spira, A.I.3
-
31
-
-
77958496605
-
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: A randomised, multicentre open-label phase II study
-
20497967 10.1093/annonc/mdq247 1:STN:280:DC%2BC3cbhsVSrtg%3D%3D
-
S Rao N Starling D Cunningham, et al. 2010 Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study Ann Oncol 21 11 2213 2219 20497967 10.1093/annonc/mdq247 1:STN:280: DC%2BC3cbhsVSrtg%3D%3D
-
(2010)
Ann Oncol
, vol.21
, Issue.11
, pp. 2213-2219
-
-
Rao, S.1
Starling, N.2
Cunningham, D.3
-
32
-
-
77957552916
-
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: Dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial
-
20679619 10.1200/JCO.2010.29.2847 1:CAS:528:DC%2BC3cXht1eqsbzJ
-
AFC Okines SE Ashley D Cunningham, et al. 2010 Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial J Clin Oncol 28 25 3945 3950 20679619 10.1200/JCO.2010.29. 2847 1:CAS:528:DC%2BC3cXht1eqsbzJ
-
(2010)
J Clin Oncol
, vol.28
, Issue.25
, pp. 3945-3950
-
-
Okines, A.F.C.1
Ashley, S.E.2
Cunningham, D.3
-
33
-
-
82755167862
-
Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5- fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: Results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
-
22152101 10.1186/1471-2407-11-509 1:CAS:528:DC%2BC38XitFegs74%3D
-
B Luber J Deplazes G Keller, et al. 2011 Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO) BMC Cancer 11 509 22152101 10.1186/1471-2407-11-509 1:CAS:528:DC%2BC38XitFegs74%3D
-
(2011)
BMC Cancer
, vol.11
, pp. 509
-
-
Luber, B.1
Deplazes, J.2
Keller, G.3
-
34
-
-
84865698216
-
Analysis of biomarker expression (ki67, EGFR, HER2, ERK, NFkB, and mTOR) in patients with advanced gastric and gastroesophageal junction (GEJ) cancer treated with cetuximab plus cisplatin/docetaxel: DOCETUX study
-
abstr 4133
-
Pinto C, Mutri V, Di Fabi F. Analysis of biomarker expression (ki67, EGFR, HER2, ERK, NFkB, and mTOR) in patients with advanced gastric and gastroesophageal junction (GEJ) cancer treated with cetuximab plus cisplatin/docetaxel: DOCETUX study. J Clin Oncol 2010. 28(suppl; abstr 4133).
-
(2010)
J Clin Oncol
, vol.28
, Issue.SUPPL.
-
-
Pinto, C.1
Mutri, V.2
Di Fabi, F.3
-
35
-
-
72249094330
-
High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer
-
19918848 10.1002/bjs.6780 1:CAS:528:DC%2BC3cXjslOgtg%3D%3D
-
Ó Vidal JP Metges I Elizalde, et al. 2009 High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer Br J Surg 96 12 1443 1451 19918848 10.1002/bjs.6780 1:CAS:528:DC%2BC3cXjslOgtg%3D%3D
-
(2009)
Br J Surg
, vol.96
, Issue.12
, pp. 1443-1451
-
-
Vidal, Ó.1
Metges, J.P.2
Elizalde, I.3
-
36
-
-
82955165140
-
Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: A meta-analysis
-
21918901 10.1007/s00432-011-1057-2 1:CAS:528:DC%2BC3MXhsVWit7zM
-
J Chen T Li Y Wu, et al. 2011 Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis J Cancer Res Clin Oncol 137 12 1799 1812 21918901 10.1007/s00432-011-1057-2 1:CAS:528:DC%2BC3MXhsVWit7zM
-
(2011)
J Cancer Res Clin Oncol
, vol.137
, Issue.12
, pp. 1799-1812
-
-
Chen, J.1
Li, T.2
Wu, Y.3
-
37
-
-
79952355358
-
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma
-
21189380 10.1200/JCO.2010.32.0770 1:CAS:528:DC%2BC3MXktlelsLc%3D
-
MA Shah M Jhawer DH Ilson, et al. 2011 Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma J Clin Oncol 29 7 868 874 21189380 10.1200/JCO.2010.32.0770 1:CAS:528:DC%2BC3MXktlelsLc%3D
-
(2011)
J Clin Oncol
, vol.29
, Issue.7
, pp. 868-874
-
-
Shah, M.A.1
Jhawer, M.2
Ilson, D.H.3
-
38
-
-
33846629672
-
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma
-
17114652 10.1200/JCO.2006.08.0887 1:CAS:528:DC%2BD28XhtlemurbM
-
MA Shah RK Ramanathan DH Ilson, et al. 2006 Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma J Clin Oncol 24 33 5201 5206 17114652 10.1200/JCO.2006.08.0887 1:CAS:528:DC%2BD28XhtlemurbM
-
(2006)
J Clin Oncol
, vol.24
, Issue.33
, pp. 5201-5206
-
-
Shah, M.A.1
Ramanathan, R.K.2
Ilson, D.H.3
-
39
-
-
56849089479
-
Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer
-
abstr 97
-
Enzinger P, Ryan D, Regan E. Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. JCO 2008;26(4552):p. abstr 97.
-
(2008)
JCO
, vol.26
, Issue.4552
-
-
Enzinger, P.1
Ryan, D.2
Regan, E.3
-
40
-
-
77957160694
-
A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers
-
20332133 10.1093/annonc/mdq065 1:STN:280:DC%2BC3cfktFarsw%3D%3D
-
BF El-Rayes M Zalupski T Bekai-Saab, et al. 2010 A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers Ann Oncol 21 10 1999 2004 20332133 10.1093/annonc/mdq065 1:STN:280:DC%2BC3cfktFarsw%3D%3D
-
(2010)
Ann Oncol
, vol.21
, Issue.10
, pp. 1999-2004
-
-
El-Rayes, B.F.1
Zalupski, M.2
Bekai-Saab, T.3
-
41
-
-
80053573446
-
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study
-
21844504 10.1200/JCO.2011.36.2236 1:CAS:528:DC%2BC3MXhsFams7bM Phase III randomised trial demonstrating lack of efficacy for bevacizumab plus chemotherapy in gastric cancer patient population, albeit with regional differences in efficacy noted.
-
A Ohtsu MA Shah E Van Cutsem, et al. 2011 Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study J Clin Oncol 29 30 3968 3976 21844504 10.1200/JCO.2011.36.2236 1:CAS:528:DC%2BC3MXhsFams7bM Phase III randomised trial demonstrating lack of efficacy for bevacizumab plus chemotherapy in gastric cancer patient population, albeit with regional differences in efficacy noted.
-
(2011)
J Clin Oncol
, vol.29
, Issue.30
, pp. 3968-3976
-
-
Ohtsu, A.1
Shah, M.A.2
Van Cutsem, E.3
-
42
-
-
79955530260
-
Preliminary safety data from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or oesophagogastric junction (OGJ) adenocarcinoma
-
Okines A, Langley R, Cafferty F, et al. Preliminary safety data from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or oesophagogastric junction (OGJ) adenocarcinoma. J Clin Oncol 2010;28 (15 suppl:4019).
-
(2010)
J Clin Oncol
, vol.28
, Issue.15 SUPPL. 4019
-
-
Okines, A.1
Langley, R.2
Cafferty, F.3
-
43
-
-
84859407803
-
Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response observed in adenocarcinoma
-
abstr 41
-
Ilson D, Janjigian Y, Shah M. Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response observed in adenocarcinoma. J Clin Oncol 2011;29(suppl 4; abstr 41).
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL. 4
-
-
Ilson, D.1
Janjigian, Y.2
Shah, M.3
-
44
-
-
84856524126
-
Phase i dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer
-
20839031 10.1007/s10637-010-9531-2 1:CAS:528:DC%2BC38XotVWgsA%3D%3D
-
C Kim J-L Lee Y Choi, et al. 2012 Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer Invest New Drugs 30 1 306 315 20839031 10.1007/s10637-010-9531-2 1:CAS:528:DC%2BC38XotVWgsA%3D%3D
-
(2012)
Invest New Drugs
, vol.30
, Issue.1
, pp. 306-315
-
-
Kim, C.1
Lee, J.-L.2
Choi, Y.3
-
45
-
-
77954574658
-
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203
-
20458043 10.1200/JCO.2009.27.7988 1:CAS:528:DC%2BC3cXptlajtb4%3D
-
W Sun M Powell PJ O'Dwyer, et al. 2010 Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203 J Clin Oncol 28 18 2947 2951 20458043 10.1200/JCO.2009.27.7988 1:CAS:528: DC%2BC3cXptlajtb4%3D
-
(2010)
J Clin Oncol
, vol.28
, Issue.18
, pp. 2947-2951
-
-
Sun, W.1
Powell, M.2
O'Dwyer, P.J.3
-
46
-
-
79958803154
-
An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer
-
21561763 10.1016/j.ejca.2011.04.006 1:CAS:528:DC%2BC3MXnsleju7s%3D
-
M Moehler A Mueller JT Hartmann, et al. 2011 An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer Eur J Cancer 47 10 1511 1520 21561763 10.1016/j.ejca.2011.04.006 1:CAS:528:DC%2BC3MXnsleju7s%3D
-
(2011)
Eur J Cancer
, vol.47
, Issue.10
, pp. 1511-1520
-
-
Moehler, M.1
Mueller, A.2
Hartmann, J.T.3
-
47
-
-
84861595716
-
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
-
Bang Y-J, Kang Y-K, Kang W, et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Investigational New Drugs 2010; p. 1-10.
-
(2010)
Investigational New Drugs
, pp. 1-10
-
-
Bang, Y.-J.1
Kang, Y.-K.2
Kang, W.3
-
48
-
-
82255194078
-
MTOR as a therapeutic target in patients with gastric cancer
-
21898386 10.1002/ijc.26396 1:CAS:528:DC%2BC3MXhsFaru7vK
-
S-E Al-Batran M Ducreux A Ohtsu 2012 mTOR as a therapeutic target in patients with gastric cancer Int J Cancer 130 3 491 496 21898386 10.1002/ijc.26396 1:CAS:528:DC%2BC3MXhsFaru7vK
-
(2012)
Int J Cancer
, vol.130
, Issue.3
, pp. 491-496
-
-
Al-Batran, S.-E.1
Ducreux, M.2
Ohtsu, A.3
-
49
-
-
77951635629
-
Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer
-
20231677 10.1200/JCO.2009.26.2923 1:CAS:528:DC%2BC3cXmsFyitbs%3D
-
T Doi K Muro N Boku, et al. 2010 Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer J Clin Oncol 28 11 1904 1910 20231677 10.1200/JCO.2009.26.2923 1:CAS:528:DC%2BC3cXmsFyitbs%3D
-
(2010)
J Clin Oncol
, vol.28
, Issue.11
, pp. 1904-1910
-
-
Doi, T.1
Muro, K.2
Boku, N.3
-
50
-
-
84862824218
-
Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
-
22343617 10.1038/bjc.2012.47 1:CAS:528:DC%2BC38XktVait7s%3D
-
DH Yoon MH Ryu YS Park, et al. 2012 Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum Br J Cancer 106 6 1039 1044 22343617 10.1038/bjc.2012.47 1:CAS:528:DC%2BC38XktVait7s%3D
-
(2012)
Br J Cancer
, vol.106
, Issue.6
, pp. 1039-1044
-
-
Yoon, D.H.1
Ryu, M.H.2
Park, Y.S.3
-
51
-
-
84861392332
-
Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1
-
abstr LBA3
-
Van Cutsem E, Yeh K, Bang Y. Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1. J Clin Oncol 2012;30(suppl 4; abstr LBA3).
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL. 4
-
-
Van Cutsem, E.1
Yeh, K.2
Bang, Y.3
-
52
-
-
84555202718
-
Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer
-
22042954 10.1200/JCO.2011.36.7706 1:CAS:528:DC%2BC38Xhslygs74%3D
-
F Graziano N Galluccio P Lorenzini, et al. 2011 Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer J Clin Oncol 29 36 4789 4795 22042954 10.1200/JCO.2011.36.7706 1:CAS:528:DC%2BC38Xhslygs74%3D
-
(2011)
J Clin Oncol
, vol.29
, Issue.36
, pp. 4789-4795
-
-
Graziano, F.1
Galluccio, N.2
Lorenzini, P.3
-
53
-
-
84555190809
-
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib
-
22042947 10.1200/JCO.2011.35.4928 1:CAS:528:DC%2BC38Xhslygs7w%3D
-
JK Lennerz EL Kwak A Ackerman, et al. 2011 MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib J Clin Oncol 29 36 4803 4810 22042947 10.1200/JCO.2011.35.4928 1:CAS:528:DC%2BC38Xhslygs7w%3D
-
(2011)
J Clin Oncol
, vol.29
, Issue.36
, pp. 4803-4810
-
-
Lennerz, J.K.1
Kwak, E.L.2
Ackerman, A.3
-
54
-
-
77950558200
-
Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study
-
suppl; abstr 4502
-
Jhawer MKH, Wainberg Z, Ford F. Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study. J Clin Oncol 2009;27(15s):p. (suppl; abstr 4502)
-
(2009)
J Clin Oncol
, vol.27
, Issue.15 S
-
-
Jhawer, M.K.H.1
Wainberg, Z.2
Ford, F.3
-
55
-
-
84896357316
-
Safety and Efficacy of Epirubicin, Cisplatin and Capecitabine (ECX) plus rilotumumab as first line treatment for unresectable locally advanced or metastatic gastric or esophagogastric junction carcinoma
-
Stockholm
-
Iveson T, Donehower I, DAvidenco S. Safety and Efficacy of Epirubicin, Cisplatin and Capecitabine (ECX) plus rilotumumab as first line treatment for unresectable locally advanced or metastatic gastric or esophagogastric junction carcinoma, in ECCO 2011: Stockholm.
-
(2011)
ECCO
-
-
Iveson, T.1
Donehower, I.2
Davidenco, S.3
-
56
-
-
84864281453
-
Durable complete response of metastatic gastric cancer with anti-met therapy followed by resistance at recurrence
-
22389872 10.1158/2159-8290.CD-11-0175
-
DVT Catenacci L Henderson S-Y Xiao, et al. 2011 Durable complete response of metastatic gastric cancer with anti-met therapy followed by resistance at recurrence Cancer Discovery 1 7 573 579 22389872 10.1158/2159-8290.CD-11-0175
-
(2011)
Cancer Discovery
, vol.1
, Issue.7
, pp. 573-579
-
-
Catenacci, D.V.T.1
Henderson, L.2
Xiao, S.-Y.3
-
57
-
-
84860120185
-
AZD4547: An orally bioavailable, potent and selective inhibitor of the Fibroblast Growth Factor Receptor tyrosine kinase family
-
Gavine PR, Mooney L, Kilgour E, et al. AZD4547: An orally bioavailable, potent and selective inhibitor of the Fibroblast Growth Factor Receptor tyrosine kinase family. Cancer Research 2012.
-
(2012)
Cancer Research
-
-
Gavine, P.R.1
Mooney, L.2
Kilgour, E.3
-
58
-
-
34249783442
-
AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor
-
17505008 10.1158/1078-0432.CCR-06-2743 1:CAS:528:DC%2BD2sXlt1KrtLs%3D
-
M Takeda T Arao H Yokote, et al. 2007 AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor Clin Cancer Res 13 10 3051 3057 17505008 10.1158/1078-0432.CCR-06-2743 1:CAS:528:DC%2BD2sXlt1KrtLs%3D
-
(2007)
Clin Cancer Res
, vol.13
, Issue.10
, pp. 3051-3057
-
-
Takeda, M.1
Arao, T.2
Yokote, H.3
-
59
-
-
84865675174
-
Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT)
-
abstr 3079
-
Ratain M, Schwartz G, Orza A. Brivanib (BMS-582664) in advanced solid tumors (AST): results of a phase II randomized discontinuation trial (RDT). J Clin Oncol 2011;29(suppl; abstr 3079).
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
-
-
Ratain, M.1
Schwartz, G.2
Orza, A.3
-
60
-
-
84855180351
-
Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT)
-
22199312
-
E Woll R Greil W Eisterer, et al. 2011 Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT) Anticancer Res 31 12 4439 4443 22199312
-
(2011)
Anticancer Res
, vol.31
, Issue.12
, pp. 4439-4443
-
-
Woll, E.1
Greil, R.2
Eisterer, W.3
|